Switch Therapeutics Launches with $52 Million to Advance First-of-its-Kind RNAi Technology

South San Francisco, CA, March 14. 2023 (Business Wire) -- Switch Therapeutics, a preclinical stage biotechnology company pioneering a new way to use RNA science to treat diseases, today announced its launch following $52 million of financing. The Company’s Series A was co-led by Insight Partners and UCB Ventures, with additional funding from existing investors, including Upfront Ventures and BOLD Capital Partners and new investors Eli Lilly and Company, Ono Venture Investment, Digitalis Ventures, Dolby Family Ventures, Free Flow Ventures, PhiFund Ventures and others.

Read full article here.